Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Clinical Trial: Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Sponsor and Collaborators
Assistance Publique - Hôpitaux de Paris
Contact
Contact: Zakia Idir, PhD
+33 1 4484 1747
zakia.idir@sls.aphp.fr
Principal Investigator
Celeste Lebbe, MD, PhD Hôpital Saint-Louis, Paris, France
ClinicalTrials.gov Identifier
NCT01168050
